Patent EA-001457-B1 (EA)
Title: Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
Inventor: ST CLAIR MARTHA HEIDER
IPC: A61K31/7072
Filed: 1997-06-23
Abstract: 1. A combination comprising 3S-[3R*(1R*,2S*)]-[3-[[(4-amino-phenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1(phenylmethyl)propyl]-carbamic acid, tetrahydro-3-furanyl ester or a physiologically functional derivative thereof, zidovudine or a physiologically functional derivative thereof, and (1S,4R)-cis-4-[2-amino-6(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol or a physiologically functional derivative thereof. 2. A combination comprising two compounds selected from 3S[3R*(1 R*,2S*)]-[3-[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1(phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester, zidovudine, and (1S, 4R)-cis-4-[2-amino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol is in the ratio of 1 to 20: 1 to 20: 1 to 10 by weight  3. A combination according to claims 1 or 2 for use in medical therapy. 4. A pharmaceutical formulation comprising a combination according to claims 1 or 2 in association with one or more pharmaceutically acceptable carriers therefor. 5. A formulation according to claim 4 in unit dosage form. 6. Use of 3S-[3R*(1 R*,2S*)]-[3-[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1(phenylmethyl)propyl]carbamic acid. tetrahydro-3-furanyl ester in the manufacture of a medicament for administration either simultaneously or sequentially with zidovudine and (1S,4R)-cis-4-[2-amino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, for the treatment and/or prophylaxis of a n HIV infection. 7. Use of zidovudine in the manufacture of a medicament for administration simultaneously or sequentially with 3S-[3R*(1 R*,2S*)]-[3-[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1(phenylmethyl)-propyl]carbamic acid, tetrahydro-3-furanyl ester or (1S, 4R)-cis-4-[2-armino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol for the treatment of an HIV infection. 8. Use of (1S,4R)-cis-4-[2-amino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol in the manufacture of a medicament for administration simultaneously or sequentially with 3S -3R*(1R*,2S*)]-[3-[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1(phenylmethyl)-propyl]carbamic acid, tetrahydro-3-furanyl ester or zidovudine for the treatment of an HlV infection. 9. Use of zidovudine, 3S-[3R*(1 R*,2S*)]-[3-[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester and (1S, 4R)-cis-4-(2-amino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol in the manufacture of a medicament for the treatment and/or prophylaxis of an HIV infection. 10. Use as claimed in any claim from 6 to 9 for the treatment of an HIV infection resistant to nucleoside or non-nucleoside inhibitors. 11. Use as claimed in any claim from 6 to 9 in the treatment of AIDS. 12. Use as claimed in any claim from 6 to 9 in the treatment of AIDS related conditions of AIDS dementia complex. 13. A patient pack comprising at least one active ingredient selected from 3S 3R*(1R*,2S*)]-[3-[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy(1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester, zidovudine, and (1S, 4R)-cis-4-[2-amino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol and an information insert containing directions on the use of at least 3S-[3R*(1R*,2S*)]-[3-[4(4-aminophenyl](sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1(phenylmethyl)propyl]carbamic acid, tetrahydro-3 furanyl ester and (1S,4R)-cis-4-[2-amino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol together in combination.